Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy A 30-Month Nonrandomized Controlled Open-Label Extension Trial

MLA

Mah, Jk, et al. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy A 30-Month Nonrandomized Controlled Open-Label Extension Trial. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315664179&authtype=sso&custid=ns315887.

APA

Mah, J., Clemens, P., Guglieri, M., Smith, E., Finkel, R., Tulinius, M., Nevo, Y., Ryan, M., Webster, R., Castro, D., Kuntz, N., McDonald, C., Damsker, J., Schwartz, B., Mengle-Gaw, L., Jackowski, S., Stimpson, G., Ridout, D., Ayyar-Gupta, V., … Dang, U. (2022). Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy A 30-Month Nonrandomized Controlled Open-Label Extension Trial.

Chicago

Mah, Jk, Pr Clemens, M Guglieri, Ec Smith, Rs Finkel, M Tulinius, Y Nevo, et al. 2022. “Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy A 30-Month Nonrandomized Controlled Open-Label Extension Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315664179&authtype=sso&custid=ns315887.